Gastrinomas: Advances in Diagnosis and Management
- 1 October 2004
- journal article
- research article
- Published by S. Karger AG in Neuroendocrinology
- Vol. 80 (Suppl. 1) , 23-27
- https://doi.org/10.1159/000080736
Abstract
Gastrinomas causing Zollinger-Ellison syndrome (ZES) are the most common functional, malignant pancreatic endocrine tumors. In this paper, the diagnosis and treatment of these tumors are reviewed, incorporating recent advances in each area. Furthermore, recent advances in their pathology, molecular pathogenesis, and aspects of their localization using somatostatin receptor scintigraphy, as well as their treatment are discussed. Recent data from our NIH prospective studies on patients with ZES are included to illustrate many of these points.Keywords
This publication has 18 references indexed in Scilit:
- Does the Use of Routine Duodenotomy (DUODX) Affect Rate of Cure, Development of Liver Metastases, or Survival in Patients With Zollinger-Ellison Syndrome?Annals of Surgery, 2004
- Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tractExpert Opinion on Pharmacotherapy, 2002
- Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinomaCancer, 2002
- Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger–Ellison syndrome?Alimentary Pharmacology & Therapeutics, 2001
- Gastric Secretion in Zollinger-Ellison SyndromeMedicine, 2001
- Surgery to Cure the Zollinger–Ellison SyndromeNew England Journal of Medicine, 1999
- Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1Journal of Internal Medicine, 1998
- Determinants of metastatic rate and survival in patients with zollinger-ellison syndrome: A prospective long-term studyGastroenterology, 1995
- Secretin and Calcium Provocative Tests in the Zollinger-Ellison SyndromeAnnals of Internal Medicine, 1989